Dialysis to assist the patient in clearing the drug (may be difficult to obtain access for dialysis catheters).Supportive therapy to allow the patient to clear the dabigatran (not a great option for a patient with life-threatening bleeding).When health care providers were previously faced with the need for urgent reversal of dabigatran, there were few options available, and none of them were ideal in life-threatening situations. ![]() ![]() The FDA has granted accelerated approval for Boehringer Ingelheim’s idarucizumab (Praxbind), the first product specifically targeted to reverse the effects of dabigatran (Pradaxa).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |